Renovacor is a preclinical stage biotechnology company whose mission is to develop improved therapies for genetically derived cardiovascular diseases. It is currently developing a gene therapy for a rare, familial form of dilated cardiomyopathy. The company's lead gene therapy product aims to restore cardiac function in patients with symptomatic heart failure due to BAG3 gene mutation.